The global pharmaceutical industry gathers this week at CPHI Frankfurt 2025 from October 28–30. As a global leading ...

MALVERN, Pa.--(BUSINESS WIRE)--Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development ...

The plant-based API market is primed for growth due to heightened demand for sustainable, natural therapeutics and regulatory acceptance. Advances in extraction and purification improve reliability ...

Enhanc3D Genomics has announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery. The new 3D multi-omics offerings were designed to ...

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced ...

HUNT VALLEY, Md.--(BUSINESS WIRE)--Pharmaceutics International, Inc. (Pii), a trusted provider of pharmaceutical development and manufacturing services, today announced the launch of its pioneering ...

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug ...

RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President ...

Thermo Fisher Scientific says addressing the need for prefilled syringes is among potential production bottlenecks, the company is working to address. Thermo Fisher’s Accelerator™ Drug Development ...

RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug ...

MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), ...